HYQVIA
161403
Phase 3 mab completed
Quick answer
HYQVIA for Chronic Inflammatory Demyelinating Polyradiculoneuropathy is a Phase 3 program (mab) at Takeda Pharmaceuticals International AG with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Phase
- Phase 3
- Modality
- mab
- Status
- completed